H.C. Wainwright maintains a Buy rating and $7 price target on Clene shares after the company announced updated survival data from its Phase 2 RESCUE-ALS open label extension study. The updated data “impress,” says the firm, which believes these data, if they continue to hold, “position the therapy for regulatory, clinical, and commercial successes.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CLNN:
- Clene to Present at Upcoming September Conferences
- Clene Reports Significantly Improved Survival Benefit of 19.3 Months and Significantly Delayed Clinical Worsening in Rescue-Als Open-Label Extension Two Year Follow-Up
- Clene Nanomedicine reports 24-month data from Phase 2 RESCUE-ALS
- Clene expects cash to fund operations into mid-2024
- Clene reports Q2 EPS (29c), consensus (12c)